PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer

2013-11-06
(Press-News.org) Contact information: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer Long term results of the randomized phase III EORTC intergroup trial 40983 were recently reported in The Lancet Oncology. The observed 4.1% difference in overall survival at five years for patients with initially resectable liver metastases from colorectal cancer was not significant for perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) compared with surgery alone. Earlier results of this same trial had shown that perioperative chemotherapy with FOLFOX4 increases progression-free survival (the primary endpoint) compared with surgery alone for these patients. Overall survival was a secondary endpoint, and the trial was not initially powered to compare overall survival in the two groups. Consequently, the authors conclude that perioperative chemotherapy with FOLFOX4 should remain the reference treatment for this population of patients.

Prof. Bernard Nordlinger of the Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique–Hôpitaux de Paris, Université de Versailles, Boulogne- Billancourt, France, and member of the EORTC Gastrointestinal Tract Cancer Group says, "Surgery is currently the only potentially curative treatment for resectable liver metastases, yet only 15–20% of patients with hepatic metastases are initially eligible for a radical surgical treatment. Furthermore, less than one half of patients who do receive such treatment achieve 5-year survival after resection. This is likely due to the presence of residual disease, so it is thought that adjuvant chemotherapy could help these patients."

EORTC intergroup trial 40983 recruited 364 patients between the ages of 18-80 years with colorectal cancer and up to four liver metastases. Patients were randomly assigned to either perioperative FOLFOX4, 182 patients, or surgery alone, 182 patients. Of these, eleven patients per group were deemed to be ineligible.

At a median follow-up of 8.5 years (Interquartile range 7•6 years–9•5 years), 59% of all randomized patients in the perioperative chemotherapy group had died as opposed to 63% in the surgery alone group (Hazard ratio 0.88, 95% confidence interval (CI) 0•68–1•14; p=0•34). Median overall survival was 61.3 months (95% CI 51.0–83.4) for patients receiving perioperative chemotherapy and 54.3 months (95% CI 41.9–79.4) for those receiving surgery alone, while the 5-year overall survival was 51.2% (95% CI 43.6–58.3) in the perioperative chemotherapy group and 47.8% (95% CI 40.3–55.0) in the surgery-only group. In eligible patients (171 per group), estimated 5-year overall survival was 52.4% in the perioperative chemotherapy group versus 48.3% in the surgery alone group.

Five patients (two patients in the perioperative chemotherapy group and three in the surgery-only group) passed away due to complications from surgery. One additional death in the perioperative chemotherapy group was possibly a result of toxicity from the protocol treatment.

### EORTC trial 40983 was coordinated by the EORTC Gastrointestinal Tract Cancer Group in collaboration with Australasian Gastro-Intestinal Trials Group, Arbeitsgruppe Lebermetastasen und -tumoren in der Chirurgischen, Arbeitsgemeinschaft Onkologie, Cancer Research Campaign Clinical Trials Unit – UK, and Fédération Francophone de Cancérologie Digestive. It was conducted at 78 hospitals located in eleven countries: Australia, Austria, Belgium, France, Germany, Hong Kong, Italy, Norway, Sweden, The Netherlands, and the United Kingdom.

This trial was supported by an educational grant from Sanofi -Aventis, by grants from the Norwegian and Swedish Cancer Societies, Cancer Research UK, and the Ligue Nationale Contre le Cancer (France) through the EORTC Charitable Trust, and the United States of America National Cancer Institute grants 5U10-CA11488-28 to 5U10 CA11488-40.


ELSE PRESS RELEASES FROM THIS DATE:

For young baseball players, light bats don't hit too fast

2013-11-06
For young baseball players, light bats don't hit too fast PROVIDENCE, R.I. [Brown University] — With some fierce pitching on display, this year's World Series featured its share of shattered wood bats. That's a problem many youth baseball players avoid by using ...

'Path to 2025' Alzheimer's Disease Summit: Reforms urgently needed to streamline road to Alzheimer's

2013-11-06
'Path to 2025' Alzheimer's Disease Summit: Reforms urgently needed to streamline road to Alzheimer's New report provides specific recommendations for governments, academia, and industry to reduce costs and increase efficiency in Alzheimer's R&D so new drugs ...

Prognostic value of baseline HRQOL for survival for 11 types of cancer pointed out by EORTC study

2013-11-06
Prognostic value of baseline HRQOL for survival for 11 types of cancer pointed out by EORTC study Results of an EORTC study published in Cancer point out the prognostic value of baseline recorded health-related quality of life for survival for ...

Nature's great diversity: Remarkable 277 new wasp species from Costa Rica

2013-11-06
Nature's great diversity: Remarkable 277 new wasp species from Costa Rica Costa Rica reveals astonishing biodiversity of braconid wasps, with 277 new species of the tribe Heterospilini described in the latest special issue of the open access journal ZooKeys. This is the second ...

Touch may alleviate existential fears for people with low self-esteem

2013-11-06
Touch may alleviate existential fears for people with low self-esteem As human beings, we all know that we are going to die some day. Most of us deal with this knowledge by trying to live meaningful lives, but people with low self-esteem ...

NIST's new compact atomic clock design uses cold atoms to boost precision

2013-11-06
NIST's new compact atomic clock design uses cold atoms to boost precision Physicists at the National Institute of Standards and Technology (NIST) have demonstrated a compact atomic clock design that relies on cold rubidium atoms instead ...

Cocktail novelties inspired by nature's designs

2013-11-06
Cocktail novelties inspired by nature's designs Mechanisms behind water bugs and lilies applied to culinary devices CAMBRIDGE, MA -- An MIT mathematician and a celebrity chef have combined talents to create two culinary novelties inspired by nature. John ...

Perfect faults: A self-correcting crystal may unleash the next generation of advanced communications

2013-11-06
Perfect faults: A self-correcting crystal may unleash the next generation of advanced communications Researchers from the National Institute of Standards and Technology (NIST) have joined with an international team to engineer and ...

Recent National Science Foundation study reveals increase in state government expenditures for research and development

2013-11-06
Recent National Science Foundation study reveals increase in state government expenditures for research and development According to a recent study published by the National Science Foundation (NSF), state government agency expenditures for research and development ...

Updating building energy codes: How much can your state save?

2013-11-06
Updating building energy codes: How much can your state save? How much in energy and cost savings would your state realize if it updated its commercial building energy codes? You can find out in a new on-line publication* from the National ...

LAST 30 PRESS RELEASES:

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate

Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative

Structure dictates effectiveness, safety in nanomedicine

Mission accomplished for the “T2T” Hong Kong Bauhinia Genome Project

[Press-News.org] Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer